Coronary CT Angiogram: What This Test Actually Measures and What Your Results Mean

What a Coronary CT Angiogram Actually Measures

A CCTA does not measure a number the way a cholesterol panel does. It produces an image. What your reporting cardiologist is evaluating when they read that image covers several distinct parameters, and understanding each one helps you ask better questions at your follow-up visit.

Luminal Stenosis: How Narrowed Is the Artery?

The most straightforward output is the percentage of narrowing inside each coronary artery. Stenosis is graded on a 5-point scale used in most structured CCTA reporting systems (CAD-RADS 2.0, published in the Journal of Cardiovascular Computed Tomography in 2022):

• CAD-RADS 0: No plaque, 0% stenosis
• CAD-RADS 1: Minimal plaque, 1-24% stenosis
• CAD-RADS 2: Mild stenosis, 25-49%
• CAD-RADS 3: Moderate stenosis, 50-69%
• CAD-RADS 4: Severe stenosis, 70-99% (or total occlusion)
• CAD-RADS 5: Total occlusion

A stenosis below 50% is considered non-obstructive. That does not mean harmless. Non-obstructive plaque can still rupture and cause a myocardial infarction, and this is a pattern seen disproportionately in women.

Plaque Composition: Calcified vs. Non-Calcified vs. Mixed

This is where CCTA delivers information no other non-invasive test can match as clearly. The scanner distinguishes:

Calcified plaque appears bright white. It represents older, more stable atherosclerosis, though stability is relative and calcified plaques do rupture.

Non-calcified (soft) plaque appears darker, with a density closer to surrounding tissue. It contains more lipid and inflammatory cells and is generally considered higher-risk for acute events. Data from the PROMISE trial demonstrated that non-calcified plaque burden on CCTA predicted major cardiac events independently of stenosis severity.

Mixed plaque has both components and carries intermediate risk.

High-Risk Plaque Features

Beyond composition, trained readers look for specific morphological features that predict vulnerability to rupture:

• Low-attenuation plaque (density <30 Hounsfield units, indicating a large lipid-rich necrotic core)
• Positive remodeling (the artery wall expands outward to accommodate plaque, concealing stenosis on standard angiography)
• Napkin-ring sign (a rim of low-attenuation plaque surrounding a denser core)
• Spotty calcification (small, scattered calcium deposits within a lipid-rich plaque)

The presence of two or more high-risk features qualifies as "high-risk plaque" and is now flagged explicitly in CAD-RADS 2.0 reporting with the modifier "HRP." A 2023 meta-analysis in JACC: Cardiovascular Imaging found that high-risk plaque features on CCTA were associated with a 4-fold increase in acute coronary syndrome risk compared with similar stenosis grades without those features.

Total Plaque Burden and Segment Involvement Score

Some reports include a segment involvement score (SIS) or segment stenosis score (SSS), counting how many of the 18 coronary segments defined in standard nomenclature contain any plaque, and how severely each is affected. Higher scores correlate with worse outcomes independent of the most severe stenosis seen.

Why This Test Matters Differently for Women

Women's coronary artery disease has been called "the great masquerader" for decades. The reasons are physiological, not incidental.

Female-Pattern Atherosclerosis

Women are more likely than men to develop diffuse, non-obstructive coronary artery disease rather than the focal, high-grade stenoses that dominate male-pattern disease. This means a standard stress test, which is designed to detect flow-limiting stenosis, may be entirely normal even when a woman has substantial plaque burden. CCTA visualizes that plaque directly.

Women also have smaller coronary artery diameters on average, which affects both image quality and the threshold for calling a stenosis "significant." Reporting cardiologists experienced in women's heart imaging account for vessel caliber in their interpretation.

Microvascular Disease: What CCTA Does Not Fully See

CCTA images the epicardial (large, visible) coronary arteries well. It does not directly image the coronary microcirculation, the network of tiny vessels that is the primary site of disease in many women with angina and normal or near-normal coronary arteries. MINOCA (myocardial infarction with non-obstructive coronary arteries) accounts for approximately 6-15% of all myocardial infarctions and is roughly three times more common in women than men.

If your CCTA shows no obstructive disease but you continue to have symptoms, coronary microvascular dysfunction or vasospasm should be the next diagnostic question. That requires different testing, such as coronary reactivity testing or a PET myocardial perfusion scan.

Perimenopause and Menopause: The Atherosclerosis Inflection Point

Estrogen has well-documented vasculoprotective effects, including maintaining endothelial function, keeping LDL-C lower, and supporting HDL-C. The rate of atherosclerosis progression accelerates in the years surrounding the final menstrual period. Data from the SWAN Heart Study showed that coronary artery calcification (a related but distinct measure) progressed significantly faster in women transitioning through menopause than in premenopausal women of similar age, independent of traditional cardiovascular risk factors.

This means a CCTA obtained at age 55 in a postmenopausal woman may show plaque burden that would be unexpected based on her LDL-C alone. The perimenopause years, roughly ages 45-55 for most women, are a critical window for cardiovascular risk assessment.

PCOS and Premature Cardiovascular Risk

If you have polycystic ovary syndrome, your cardiovascular risk profile starts shifting earlier. PCOS is associated with insulin resistance, dyslipidemia (elevated triglycerides, low HDL-C, and often elevated small dense LDL), hypertension, and chronic low-grade inflammation, all of which accelerate atherosclerosis. A 2020 systematic review in Human Reproduction Update found that women with PCOS had significantly higher rates of subclinical atherosclerosis markers compared with age-matched controls.

For a woman with PCOS in her 30s or 40s who has multiple additional risk factors, a CCTA may be appropriate earlier than standard age-based guidelines suggest.

What "Normal" Looks Like on a CCTA Report

No single number defines a normal CCTA. Your report will describe findings across multiple coronary segments. A normal (or near-normal) result typically reads as one of the following:

CAD-RADS 0: "No coronary artery plaque identified. No evidence of coronary artery disease." This is the cleanest possible result. In the CONFIRM registry, individuals with CAD-RADS 0 had an annual major cardiac event rate below 0.5%.

CAD-RADS 1: Minimal plaque present but no stenosis exceeding 24%. This is not a clean bill of health; it means atherosclerosis has begun. Risk remains low but lifestyle and risk-factor optimization are warranted.

For women specifically, a CAD-RADS 0 or 1 result with no high-risk plaque features is genuinely reassuring and, in the context of a chest pain evaluation, is associated with an excellent short-term prognosis.

What Abnormal Findings Mean and What Comes Next

Non-Obstructive Plaque (CAD-RADS 1-2)

Finding plaque that does not significantly narrow the artery is not a reason to panic, but it is a reason to act. The SCCT/ACC Chest Pain Guideline (2021) recommends intensifying preventive therapy for patients with non-obstructive CAD on CCTA, including statin therapy initiation or intensification based on 10-year ASCVD risk recalculation.

For a woman in her late 40s or early 50s with new non-obstructive plaque on CCTA, this often means:

• Initiating a statin if not already on one
• Tightening blood pressure targets (<130/80 mmHg per 2021 ACC/AHA Heart Failure Guidelines, a relevant benchmark)
• Reviewing lifestyle: diet quality, physical activity, smoking cessation
• Re-evaluating hormonal contraception if applicable (see pregnancy/contraception section)

Obstructive Plaque (CAD-RADS 3-4)

Moderate to severe stenosis on CCTA requires further evaluation. This may include:

• Coronary CT-derived fractional flow reserve (CT-FFR): A software analysis performed on the CCTA dataset that estimates whether a stenosis is actually reducing blood flow. It can be added to the original scan without additional radiation.
• Stress testing (nuclear, echo, or CMR) to assess for ischemia
• Invasive coronary angiography if revascularization is being considered

CAD-RADS 4A (70-99% stenosis in a single vessel) or 4B (left main or three-vessel severe disease) typically triggers urgent cardiology follow-up within days, not weeks.

High-Risk Plaque Features Without Severe Stenosis

This scenario is particularly relevant for women. A woman may have a CAD-RADS 2 result (mild stenosis, not severe) but with HRP modifier features. The ICONIC study demonstrated that high-risk plaque features on CCTA identified patients who subsequently had acute MI despite having stenosis below 50% at the time of imaging. Current practice in experienced centers is to treat HRP findings with the same urgency as moderate stenosis: high-intensity statin therapy, aspirin if appropriate, and close follow-up.

How the Test Is Done: A Step-by-Step Guide

Before the Scan

You will likely be asked to:

• Avoid caffeine for 12-24 hours before the scan (caffeine raises heart rate, which degrades image quality)
• Fast for 4-6 hours beforehand (reduces nausea from contrast)
• Stop metformin 48 hours before if you have diabetes and your kidney function is borderline (your prescriber should advise on this)
• Have an IV placed in your arm or hand

Your heart rate will be checked on arrival. Most CCTA protocols require a resting heart rate below 65 beats per minute for optimal image quality. If yours is higher, you will receive a short-acting beta-blocker (commonly metoprolol 25-50 mg orally or intravenously) to slow your heart.

You may also receive sublingual nitroglycerin just before scanning to dilate the coronary arteries slightly, improving visualization.

During the Scan

The scan itself takes 10-15 minutes. You will lie on the CT table, electrodes will be placed to synchronize imaging to your heartbeat (ECG gating), and iodinated contrast dye will be injected through your IV. You will feel a warm flush through your body when the contrast is given; this is normal and lasts about 30 seconds.

You will be asked to hold your breath for 5-10 seconds at one or more points during the acquisition.

After the Scan

Drink plenty of water to help your kidneys clear the contrast dye. If you received a beta-blocker, you should not drive for at least 4 hours, and you should be aware that your heart rate and blood pressure may be lower than usual for a few hours.

Results are typically read by a cardiac imaging specialist and returned to your ordering clinician within 24-72 hours.

Radiation Exposure

Modern CCTA protocols using prospective ECG-triggered acquisition deliver approximately 1-3 mSv of effective radiation dose. For context, the average American receives about 3 mSv per year from natural background radiation. A 2020 SCCT position statement confirmed that contemporary low-dose protocols have reduced CCTA radiation exposure by more than 80% compared with earlier techniques from the early 2000s.

Pregnancy, Lactation, and Contraception Considerations

Pregnancy: CCTA is contraindicated in pregnancy except in life-threatening emergencies where the clinical information cannot be obtained any other way. The concern is twofold: fetal radiation exposure from ionizing X-rays and the use of iodinated contrast, which crosses the placenta. The American College of Radiology (ACR) guidance and ACOG Committee Opinion 723 both state that iodinated contrast should be used during pregnancy only when clearly indicated and when the benefits outweigh potential fetal risks.

If you are pregnant and have symptoms that raise concern for acute coronary syndrome, your clinical team will typically prioritize electrocardiography, troponin testing, and echocardiography first, reserving radiation-based imaging for situations where the diagnosis cannot otherwise be made.

Lactation: Iodinated contrast is transferred into breast milk in very small amounts. The ACR Manual on Contrast Media notes that the amount absorbed by an infant from breast milk after a contrast-enhanced study is negligible, and current evidence does not support the need to interrupt breastfeeding after CCTA. You may choose to pump and discard milk for 12-24 hours as a precaution if you prefer, but most radiologists and lactation specialists consider continued breastfeeding safe.

Contraception considerations: CCTA is not a direct contraception-relevant test, but the findings frequently inform decisions about hormonal contraception. Combined oral contraceptives (COCs) containing estrogen increase the risk of venous thromboembolism and, in women with underlying cardiovascular disease or multiple risk factors, may increase arterial event risk. If your CCTA reveals significant plaque burden or high-risk features, your clinician will likely recommend transitioning from a COC to a progestin-only method or a non-hormonal method, in line with WHO Medical Eligibility Criteria Category 3-4 for COCs in women with ischemic heart disease.

Who This Test Is Right For (and Who Should Wait)

Women Who May Benefit Most

CCTA is most useful when the result will change clinical management. Candidates most likely to benefit include:

• Women ages 40-75 with intermediate 10-year ASCVD risk (7.5-20%) on the Pooled Cohort Equations where the decision to start a statin is uncertain
• Women with atypical chest pain or shortness of breath where stress testing has been non-diagnostic
• Women with early menopause (before age 45) as a cardiovascular risk-enhancing factor
• Women with PCOS and additional metabolic risk factors
• Women with a family history of premature coronary artery disease (first-degree relative with event before age 55 in men or 65 in women)
• Women who stopped hormone therapy and want to understand their current atherosclerotic burden

The 2019 ACC/AHA Primary Prevention Guideline lists coronary artery calcium scoring as a first-line tie-breaker for statin decisions in intermediate-risk patients. CCTA provides more information than calcium scoring alone but at higher cost and radiation, so the choice between the two depends on clinical context and your center's expertise.

Women for Whom This Test Is Less Appropriate

• Pregnant women (see above)
• Women with severe kidney disease (eGFR <30 mL/min/1.73 m2) due to contrast nephropathy risk, though this threshold is debated and risk-benefit applies
• Women with a documented allergy to iodinated contrast who have not been pre-medicated
• Women who cannot achieve adequate heart rate control for image quality (some arrhythmias, severe COPD with bronchospasm risk from beta-blockers)
• Women at very low 10-year ASCVD risk (<5%) where the pre-test probability of significant findings is too low to justify the test

Reducing Your Cardiovascular Risk After an Abnormal CCTA

An abnormal result is information, not a verdict. The appropriate response depends on what specifically was found.

Lifestyle Interventions With the Strongest Evidence

• Dietary pattern: The PREDIMED trial demonstrated that a Mediterranean-style diet supplemented with extra-virgin olive oil or nuts reduced major cardiovascular events by approximately 30% in high-risk adults. PREDIMED was published in the New England Journal of Medicine in 2013 (the corrected 2018 republication confirmed the primary findings).
• Physical activity: 150 minutes per week of moderate-intensity aerobic activity, per AHA guidelines, reduces cardiovascular mortality.
• Smoking cessation: Cessation at any age reduces cardiovascular risk, with the largest gains in the first 1-3 years.
• Blood pressure control: Target <130/80 mmHg for women with plaque on CCTA.

Pharmacotherapy

Statin therapy is the cornerstone of pharmacological risk reduction after finding plaque on CCTA. For women specifically, there has been a longstanding concern about whether statins reduce cardiovascular events in women to the same degree as in men. A 2022 meta-analysis in the Lancet of 154,000 patients found that the relative risk reduction from statins was statistically equivalent in women and men, though the absolute risk reduction differs because of baseline event rates. Women should not be undertreated because of historically incorrect assumptions about statin efficacy.

For women with LDL-C that remains above target on maximally tolerated statin therapy, ezetimibe and PCSK9 inhibitors (evolocumab, alirocumab) are additional options supported by trial data that includes women.

The WomanRx CCTA Action Framework by Life Stage:

| Life Stage | Typical Concern | If CCTA Shows Plaque | |---|---|---| | Reproductive years (20s-30s) | PCOS, premature atherosclerosis, smoking | Intensify lifestyle; reassess hormonal contraception; statin if indicated | | Perimenopausal (40s-early 50s) | Accelerating atherosclerosis around final menstrual period | Statin initiation or intensification; optimize BP; consider MHT risk-benefit if symptomatic | | Postmenopausal (<60 or <10 years since FMP) | Established plaque burden | High-intensity statin; aspirin per individual risk; cardiology co-management | | Postmenopausal (>60 or >10 years since FMP) | Higher baseline risk; polypharmacy considerations | Same as above; evaluate for microvascular disease if symptoms persist |

A Note on the Evidence Gap for Women

Women were significantly under-represented in the foundational coronary CT angiography validation trials. The PROMISE trial, which is among the largest CCTA outcome trials, enrolled approximately 53% women, which was better than many prior cardiovascular trials. The SCOT-HEART trial, which showed that CCTA-guided care reduced fatal and non-fatal MI by 41% at 5 years compared with standard care, enrolled about 40% women.

Sex-stratified analyses from both trials generally confirm benefit in women, but the absolute numbers in female subgroups are smaller. The female-specific atherosclerotic phenotype (diffuse non-obstructive disease, high-risk plaque without flow limitation, microvascular involvement) is increasingly recognized as needing tailored imaging approaches. Ongoing registries and the Women's Ischemia Syndrome Evaluation (WISE) program have contributed substantially to understanding female coronary physiology, but gaps remain.

When your clinician interprets your CCTA results, ask specifically whether the interpretation accounts for female-pattern disease features, not just CAD-RADS grade alone.